1. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36. [
DOI:10.1080/22221751.2020.1719902]
2. Bordi L, Nicastri E, Scorzolini L, Di Caro A, Capobianchi MR, Castilletti C, et al. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill. 2020;25(8):2000170. [
DOI:10.2807/1560-7917.ES.2020.25.8.2000170]
3. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;371. [
DOI:10.1136/bmj.m4471]
4. Meo S, Bukhari I, Akram J, Meo A, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9. [
link]
5. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-4. [
DOI:10.1016/S0140-6736(20)32623-4]
6. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372. [
DOI:10.1136/bmj.n699]
7. Mallapaty S, Callaway E. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine. Nature. 2021;592(7852):15-7. [
DOI:10.1038/d41586-021-00785-7]
8. Livingston EH, Malani PN, Creech CB. The Johnson and Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575. [
DOI:10.1001/jama.2021.2927]
9. Mahase E. Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots. BMJ. 2021;373. [
DOI:10.1136/bmj.n970]
10. De Matos A, Cardoso GP, Neto M. Sputnik v: Is the Russian vaccine safe. J Clin Epidemiol Toxicol. 2021;2(3):1-2. [
link]
11. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. J Travel Med. 2021;28(4):taab051. [
DOI:10.1093/jtm/taab051]
12. Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. [
DOI:10.1136/bmj.n296]
13. Griffin S. Covid-19: China's CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds. Bmj. 2021;374. [
DOI:10.1136/bmj.n1755]
14. Baraniuk C. What do we know about China's covid-19 vaccines?. BMJ. 2021;373. [
DOI:10.1136/bmj.n912]
15. Basiri N, Koushki M. Study of vaccine production abroad and scientific and research challenges of COVID-19 vaccine production in Iran. Annals Romanian Society Cell Biol. 2021;25(4):17249-56. [
link]
16. Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first?. Sci Adv. 2021;7(6):eabf1374. [
DOI:10.1126/sciadv.abf1374]
17. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-6. [
DOI:10.1126/science.abb8923]
18. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. The role of trust in the likelihood of receiving a COVID-19 vaccine: Results from a national survey. Prev Med. 2021;153:106727. [
DOI:10.1016/j.ypmed.2021.106727]
19. Keshmiri S, Darabi AH, Tahmasebi R, Vahdat K, Noroozi A. Factors influencing COVID-19 vaccine acceptance based on the behavioral change wheel model in Bushehr province in 2021: A web-based study. Hayat. 2021;27(2):190-205. [Persian] [
link]
20. French J, Deshpande S, Evans W, Obregon R. Key guidelines in developing a pre-emptive COVID-19 vaccination uptake promotion strategy. Int J Environ Res a public health. 2020;17(16):5893. [
DOI:10.3390/ijerph17165893]
21. Latkin CA, Dayton L, Yi G, Konstantopoulos A, Boodram B. Trust in a COVID-19 vaccine in the US: A social-ecological perspective. Soc Sci Med. 2021;270:113684. [
DOI:10.1016/j.socscimed.2021.113684]
22. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines. 2021;9(2): 160. [
DOI:10.3390/vaccines9020160]
23. Shekhar R, Sheikh AB, Upadhyay S, Singh M, Kottewar S, Mir H, et al. COVID-19 vaccine acceptance among health care workers in the United States. Vaccines. 2021;9(2):119. [
DOI:10.3390/vaccines9020119]
24. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors affecting COVID-19 vaccine acceptance: An international survey among low-and middle-income countries. Vaccines. 2021;9(5):515. [
DOI:10.3390/vaccines9050515]
25. Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, et al. Women's views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: A multi-methods study in the UK. BMC Pregnancy Childbirth. 2022;22(1):33. [
DOI:10.1186/s12884-021-04321-3]
26. Biswas N, Mustapha T, Khubchandani J, Price JH. The nature and extent of COVID-19 vaccination hesitancy in healthcare workers. J Community Health. 2021;46(6):1244-51. [
DOI:10.1007/s10900-021-00984-3]
27. Yoda T, Katsuyama H. Willingness to receive COVID-19 vaccination in Japan. Vaccines. 2021;9(1):48. [
DOI:10.3390/vaccines9010048]
28. Vardanjani HM, Imanieh MH, Hassani A-H, Bagheri-Lankarani K. Public trust in healthcare system and its correlates during the COVID-19 Epidemic in Iran. Researchsquare. 2020;1. [
DOI:10.21203/rs.3.rs-106242/v1]
29. Hatami S, Hatami N. The role of trust in receiving or not receiving COVID-19 vaccine. J Marine Med. 2021;3(4):20-7. [Persian] [
link]
30. Bagheri Sheykhangafshe F. COVID-19 vaccination: Challenges and opportunities. J Rafsanjan Univ Med Sci. 2022;20(11):1289-94. [Persian] [
DOI:10.52547/jrums.20.11.1289]